Peter P Toth1, Michael Grabner2, Nadia Ramey3, Keiko Higuchi4. 1. CGH Medical Center, Sterling, IL, USA; Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: Peter.Toth@cghmc.com. 2. HealthCore, Inc., Wilmington, DE, USA. Electronic address: mgrabner@healthcore.com. 3. Rutgers University, School of Health Related Professions, Newark, NJ, USA; ESAC Inc., Rockville, MD, USA. Electronic address: nadia.ramey@gmail.com. 4. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Electronic address: keiko.higuchi@novartis.com.
Abstract
OBJECTIVE: This study investigated real-world treatment patterns, healthcare utilization, and costs of hypertriglyceridemia in a large commercially insured United States population. METHODS: This observational claims study was conducted among adult patients with TG > 500 mg/dL between 01/01/2007 and 04/30/2013. Patients were stratified into mutually exclusive cohorts based on their first available TG measurement (index date): TG ≥ 1500 (Cohort A); 750 ≤ TG < 1500 (Cohort B), and 500 < TG < 750 (Cohort C). Study inclusion required ≥ 12 months of eligibility pre- (baseline) and post-index date (follow-up). Patient characteristics and outcomes were assessed descriptively. Costs associated with acute pancreatitis episodes were estimated using a Generalized Linear Model regression. RESULTS: We identified a total of 1964 patients in Cohort A, 7432 in Cohort B, and 17,500 in Cohort C. Patients were young (mean age 46-48) and mostly male (75%-80%). Treatment switching and augmentation occurred rarely, and almost 50% of patients discontinued their initial treatment. At baseline, healthcare utilization and costs were highest in Cohort A (mean all-cause medical and pharmacy costs, $8850). At follow-up, the number of patients with dyslipidemia-related office and pharmacy claims and related costs almost doubled across the cohorts. Mean all-cause costs/patient in Cohort A at follow-up were $12,642, of which $3730 were dyslipidemia-related. Acute pancreatitis episodes were associated with >300% increase in total all-cause costs in Cohort A. CONCLUSIONS: These results suggest that severe hypertriglyceridemia is undertreated and healthcare utilization and costs scale with magnitude of TG elevation. Patients with more severe hypertriglyceridemia received greater medical and pharmacy services. Managing severe hypertriglyceridemia more aggressively and preventing acute pancreatitis may generate cost savings.
OBJECTIVE: This study investigated real-world treatment patterns, healthcare utilization, and costs of hypertriglyceridemia in a large commercially insured United States population. METHODS: This observational claims study was conducted among adult patients with TG > 500 mg/dL between 01/01/2007 and 04/30/2013. Patients were stratified into mutually exclusive cohorts based on their first available TG measurement (index date): TG ≥ 1500 (Cohort A); 750 ≤ TG < 1500 (Cohort B), and 500 < TG < 750 (Cohort C). Study inclusion required ≥ 12 months of eligibility pre- (baseline) and post-index date (follow-up). Patient characteristics and outcomes were assessed descriptively. Costs associated with acute pancreatitis episodes were estimated using a Generalized Linear Model regression. RESULTS: We identified a total of 1964 patients in Cohort A, 7432 in Cohort B, and 17,500 in Cohort C. Patients were young (mean age 46-48) and mostly male (75%-80%). Treatment switching and augmentation occurred rarely, and almost 50% of patients discontinued their initial treatment. At baseline, healthcare utilization and costs were highest in Cohort A (mean all-cause medical and pharmacy costs, $8850). At follow-up, the number of patients with dyslipidemia-related office and pharmacy claims and related costs almost doubled across the cohorts. Mean all-cause costs/patient in Cohort A at follow-up were $12,642, of which $3730 were dyslipidemia-related. Acute pancreatitis episodes were associated with >300% increase in total all-cause costs in Cohort A. CONCLUSIONS: These results suggest that severe hypertriglyceridemia is undertreated and healthcare utilization and costs scale with magnitude of TG elevation. Patients with more severe hypertriglyceridemia received greater medical and pharmacy services. Managing severe hypertriglyceridemia more aggressively and preventing acute pancreatitis may generate cost savings.
Authors: Riyaz S Patel; Laura Pasea; Handrean Soran; Paul Downie; Richard Jones; Aroon D Hingorani; Dermot Neely; Spiros Denaxas; Harry Hemingway Journal: Cardiovasc Diabetol Date: 2022-06-09 Impact factor: 8.949
Authors: Maureen Sampson; Rami A Ballout; Daniel Soffer; Anna Wolska; Sierra Wilson; Jeff Meeusen; Leslie J Donato; Erica Fatica; James D Otvos; Eliot A Brinton; Robert S Rosenson; Peter Wilson; Marcelo Amar; Robert Shamburek; Sotirios K Karathanasis; Alan T Remaley Journal: Lipids Health Dis Date: 2021-11-27 Impact factor: 3.876
Authors: Wilhelm P Greffrath; Jesslee M du Plessis; Michelle Viljoen; Marike Cockeran Journal: South Afr J HIV Med Date: 2018-06-26 Impact factor: 2.744